Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148545 | 0.90 | F10 (0.38) | F10IDO1NPC1RAB9AMALT1 | |
| SCHEMBL590692 | 0.90 | F10 (0.37) | F10IDO1NPC1RAB9AMALT1 | |
| SCHEMBL1148604 | 0.90 | MALT1 (0.37) | F10SLC6A9IDO1MALT1NAMPT | |
| SCHEMBL1148202 | 0.89 | IDO1 (0.34) | F10SLC6A9IDO1MALT1NAMPT | |
| SCHEMBL1148471 | 0.89 | HTT (0.41) | F10IDO1MALT1POLB | |
| SCHEMBL1148359 | 0.88 | F10 (0.35) | F10IDO1NPC1RAB9AMALT1 | |
| SCHEMBL1148408 | 0.88 | F10 (0.36) | F10IDO1NPC1RAB9ARBP4 | |
| SCHEMBL1148144 | 0.87 | F10 (0.37) | F10SLC6A9IDO1NPC1RAB9A | |
| SCHEMBL1148200 | 0.86 | SLC6A9 (0.36) | SLC6A9IDO1NPC1RAB9AHMOX1 | |
| SCHEMBL1148683 | 0.86 | SLC6A9 (0.40) | F10SLC6A9MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264021-B1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264021-A1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | F10 934/4885SLC6A9 3705/4885IDO1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.